5 / 6
Page 23
allied
academies
November 21-22, 2019 | Singapore
Global Experts Meeting on
12
th
International Conference on
STD-AIDS and
Infectious Diseases
Allergy, Immunology
and Rheumatology
Joint Event
&
J Infectious Disease Med Microbiol, Volume 3
Notes:
A trivalent vaccine candidate against brucellosis
Sonal Gupta
and
Rakesh Bhatnagar
Jawaharlal Nehru University, India
T
he current vaccines against brucellosis namely B. abortus
Strain 19 and RB51, are able to prevent Brucellosis
infection in animals but are still far from ideal in offering
complete protection against the disease. Moreover they
are infectious to the human hosts as well as pose potential
risks to recipient animals e.g. attenuation reversal and
virulence in susceptible hosts on administration. Therefore,
recombinant subunit vaccines prove to be better alternatives
for combating brucellosis. BP26, Omp25 and L7/L12 are
proposed to be promising protective antigens by inducing
heightened antibody titres in conjugation with strong cell-
mediated immune responses against Brucellosis infection.
The main goal of the present study is to determine the
prophylactic potential of a Combined Subunit vaccine (CSV)
against brucellosis consisting of BP26, Omp25 and L7/L12
ribosomal protein of Brucella abortus. On co-immunization
of BP26, Omp25 and L7/L12, It was observed that total IgG
antibody levels in combined subunit vaccinewere comparable
to the mice immunized with BP26, Omp25 and L7/L12
individually. Robust humoral and cellular immune response
was suggested by higher IgG1 and IgG2a levels in mice
immunized with Combined Subunit vaccine candidate (CSV).
The effect of formulations on T-helper (Th) cell development
was assessed by quantifying the Th1-dependant (IFN-γ,
IL-2 and TNF-α) and Th2-dependant (IL-5, IL-10) cytokines.
Evidently, the simultaneous immunizationwith three antigens
complimented immune responses against its components.
Altogether, this study shows immune responses analysis on
co-immunization of BP26, Omp25 and L7/L12 proteins as a
vaccine candidate against Brucella species infection.
Speaker Biography
Sonal Gupta is a research scholar working on formulation of recombinant
vaccines against infectious diseases such as Brucellosis, anthrax. She
completed her MSc in Biotechnology from School of Biotechnology,
JNU. Currently she is pursuing PhD in Biotechnology from Jawaharlal
Nehru University, New Delhi. Her research interests include studying
immunological responses of host in response of bacterial diseases,
recombinant vaccines formulation against bacterial infectious diseases.
e:
sonalmole@gmail.comJournal of Infectious Diseases and Medical Microbiology | Volume 3